Shuhua Wei

Dr. Shuhua Wei

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
MLMengyuan Li
Mengyuan Li
PJPing Jiang
Ping Jiang
SWShuhua Wei
Shuhua Wei
YYYuhan Yang
Yuhan Yang
LXLiting Xiong
Liting Xiong
CLChunxiao Li
Chunxiao Li
Background: Understanding the molecular mechanisms driving oncogenic processes in glioma is important in order to develop efficient treatments. Recent studies have proposed gasdermin D (GSDMD) as a newly discovered pyroptosis executive protein associated with tumorigenesis. However, the precise effect of GSDMD on glioma progression remains unknown. Methods: The expression levels of GSDMD in 931 glioma and 1157 normal control tissues were collected. A series of bioinformatic approaches and in vivo and in vitro experiments were used to investigate the roles and mechanisms of GDSMD in glioma. Results: Significant upregulation of GSDMD was detected in glioma tissues compared to normal brain tissues. Patients with glioma and higher GSDMD levels had shorter overall survival, and the Cox regression analysis revealed that GSDMD was an independent risk factor. In addition, upregulation of GSDMD was associated with higher tumor mutation burden and PD-1/PD-L1 expression. Immune infiltration and single-cell analyses indicated that GSDMD was positively associated with an immunosuppressive microenvironment with more infiltrated macrophages and cancer-associated fibroblasts. Furthermore, the in vitro and in vivo experiments revealed that GSDMD knockdown inhibited glioma proliferation, migration, and growth in vivo. Conclusion: Our analyses revealed a relatively comprehensive understanding of the oncogenic role of GSDMD in glioma. GSDMD is a promising prognostic biomarker and a potential target for glioma treatment.

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SWShuhua Wei
Shuhua Wei
Xiaofan LiXiaofan Li
Xiaofan Li
ZLZi Liu
Zi Liu
LWLichun Wei
Lichun Wei
LZLijuan Zou
Lijuan Zou
JWJunjie Wang
Junjie Wang
Wei S, et al. J Gynecol Oncol. 2025 Dec;37:e46. https://doi.org/10.3802/jgo.2026.37.e46

1 January 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
HXHui Xiao
Hui Xiao
FGFuxin Guo
Fuxin Guo
ZWZhenyu Wang
Zhenyu Wang
KPKangjia Pei
Kangjia Pei
SWShuhua Wei
Shuhua Wei
PJPing Jiang
Ping Jiang
Cervical cancer (CC) remains a leading cause of cancer-related mortality, particularly in low- and middle-income countries (LMICs), despite advancements in HPV vaccination and screening. Radiotherapy (RT) plays a critical role in managing CC, but conventional fractionated radiotherapy (CFRT) is limited by long treatment durations, which reduce patient adherence, increase the risk of treatment interruptions, and impair healthcare access in LMICs. Moderately hypofractionated radiotherapy (MHRT) may offer a promising alternative, delivering higher doses per fraction with fewer total fractions, thus shortening treatment duration and alleviating the burden on both patients and healthcare systems. Early clinical data suggest that MHRT achieve acceptable short- to medium-term tumor control with manageable toxicity. However, the small sample sizes and limited follow-up in published studies preclude definitive conclusions about long-term efficacy and safety. This review synthesizes the existing clinical evidence to outline the potential benefits and inherent limitations of MHRT in CC management and highlight the need for future large-scale, long-term randomized controlled trials with rigorous quality assurance protocols. These findings also have implications for the potential implementation of MHRT in LMICs.